Juno paying $24M to settle JCAR015 class action suit

The Juno Therapeutics Inc. subsidiary of Celgene Corp. (NASDAQ:CELG) and three of its executive officers will pay stockholders $24 million to settle a class action suit related to discontinued CAR T cell therapy JCAR015.

Under the settlement, Juno, its President and CEO Hans Bishop, CFO and Head of Corporate Development Steve Harr and SVP and CMO Mark Gilbert will pay the sum to investors who bought stock in the company between June 4, 2016 and Nov. 22, 2016...